Eptinezumab
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion. Eptinezumab was approved for medical use in the United States in February 2020, and in the European Union in January 2022.
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion. Eptinezumab was approved for medical use in the United States in February 2020, and in the European Union in January 2022.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1336074211 under CC BY-SA 4.0; modifications have been made.